welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP).
expertly curated content related to this topic
- Ursodeoxycholic Acid Counteracts Celecoxib in Reduction of Duodenal Polyps in Patients With Familial Adenomatous Pol...BACKGROUND: Due to prophylactic colecto...
- New treatment reduces precancerous polyps in hereditary cancer patientsInheriting a mutation in the APC gene le...
- Ostomy: Diet and Nutrition GuideThis guide provides some basic informati...
- BCIR – Olympia Medical Center Los Angeleshttps://www.youtube.com/channel/UCEdZLy_...
- Sulindac Sulfone Induced Regression of Rectal Polyps in Patients with Familial Adenomatous PolyposisSulindac sulfone (Exisulind), a metaboli...
- Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)This is a 36 week dietary intervention p...
- Curcumin in Treating Patients With Familial Adenomatous PolyposisThis clinical trial studies curcumin in ...
English
Portuguese
Spanish